The present invention relates to compounds of general formulaI,Iwherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.本發明係關於通式I化合物，I其中基團R、R1、R2、R3、m及n如技術方案1所定義，其具有有價值之藥理學特性，特定言之其會與GPR40受體結合且調節其活性。該等化合物適用於治療及預防可受此受體影響之疾病，諸如代謝疾病，尤其2型糖尿病。此外，本發明係關於可用於合成式I化合物之新穎中間產物。
